Continuous Renal Replacement Therapy Market By Product Type (CRRT Systems, CRRT Consumables, Dialysates & Replacement Fluids); By Modality (CVVH, CVVHDF, CVVHD, SCUF); By Application (Acute Kidney Injury, Sepsis-Associated Acute Kidney Injury, Fluid Overload, Pediatric & Neonatal Acute Kidney Injury, Cardiac Surgery-Associated Acute Kidney Injury); By End User (Hospitals, ASCs, Dialysis Clinics, Others); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Continuous Renal Replacement Therapy (CRRT) Market: ICU Kidney Support Systems Scale Through AKI Burden, FDA-Cleared Platforms, and Consumable-Driven Critical Care 

The Global Continuous Renal Replacement Therapy Market is valued at USD 1.62 billion in 2025 and is expected to reach USD 2.85 billion by 2032, registering a CAGR of 7.3%.

 

The Continuous Renal Replacement Therapy (CRRT) Market is characterized by intensive care unit–based extracorporeal renal support for critically ill patients with acute kidney injury, fluid overload, sepsis-associated renal dysfunction, and multi-organ failure. CRRT is indicated when intermittent hemodialysis is not tolerated due to hemodynamic instability, often in patients requiring vasopressor support, mechanical ventilation, or continuous multi-organ support. The market is well established but remains commercially significant, as utilization is driven by ICU acuity rather than elective procedural demand.

 

The clinical demand base for continuous renal replacement therapy is substantial, as acute kidney injury affects a significant proportion of critically ill intensive care unit patients, with severe cases requiring dialysis associated with reported mortality rates exceeding 50% in high-acuity settings. Consequently, CRRT is positioned as a life-sustaining intervention rather than an elective dialysis modality. Market dynamics are therefore influenced by ICU capacity, sepsis prevalence, cardiac surgery–related complications, nephrology–critical care integration, and the repeated utilization of filters, blood circuits, dialysates, and replacement fluids across extended treatment cycles. [National Institutes of Health]

 

The approved product base provides a clearly defined regulatory foundation for the continuous renal replacement therapy device market. Baxter’s PrisMax Control Unit is FDA-cleared for CRRT in patients weighing 20 kg or more with acute renal failure and/or fluid overload, supporting SCUF, CVVH, CVVHD, and CVVHDF modalities. FDA documentation also references dedicated disposable CRRT sets used with the system, including M60/M100/M150 and HF1000/HF1400 configurations. [Baxter UK] [U.S. Food and Drug Administration]

 

In the pediatric segment, the CARPEDIEM System is classified by the FDA as a Class II device for the treatment of acute kidney injury or fluid-overloaded patients weighing 2.5–10 kg. Quanta’s Dialysis System has received expanded FDA 510(k) clearance for CVVHD and SCUF, positioning it as a compact acute-care platform supporting intermittent hemodialysis, sustained low-efficiency dialysis, and bagless CRRT within a single system. [Federal Register] [Quanta Dialysis Technologies]

 

Continuous Renal Replacement Therapy Market Segment Analysis

By product type, continuous renal replacement therapy systems remain the dominant segment, as they constitute the core capital equipment required to deliver continuous renal support in intensive care settings. Adoption is concentrated around FDA-cleared platforms, including Baxter’s PrisMax Control Unit, Fresenius Medical Care’s multiFiltratePRO, the pediatric CARPEDIEM system, and Quanta’s dialysis system. PrisMax supports SCUF, CVVH, CVVHD, and CVVHDF modalities for patients weighing 20 kg or more with acute renal failure and/or fluid overload, while the CARPEDIEM system is specifically designed for the pediatric 2.5–10 kg patient population, where standard adult platforms are not clinically appropriate. [FDA — K193482 PrisMax Control Unit 510(k) Summary | FDA — DEN180055 CARPEDIEM System De Novo Classification | FDA — K220281 multiFiltratePRO System 510(k) Premarket Notification | FDA — K222067 SC+ Hemodialysis Device 510(k) Premarket Notification | NIH/PMC — Cefepime Dosing in a Critically Ill Neonate Receiving Continuous Renal Replacement Therapy]

CRRT consumables represent the primary recurring revenue segment, as each treatment cycle requires hemofilters, tubing sets, blood circuits, anticoagulation components, and disposable extracorporeal assemblies. Demand in this segment is closely tied to therapy duration, circuit clotting rates, ICU length of stay, and infection-control replacement protocols. Unlike capital CRRT systems, consumable utilization scales with patient-days, sustaining commercial relevance even in mature hospital settings.

Dialysates and replacement fluids are essential consumables but are largely governed by treatment protocols. Their utilization is driven by modality selection, effluent dosing requirements, electrolyte correction, phosphate control, and acid–base management in prolonged acute kidney injury care. While these products are not primary determinants of equipment choice, they remain critical for maintaining metabolic stability in critically ill ICU patients with renal failure.[NCBI Bookshelf — Continuous Renal Replacement Therapy | NIH/PMC — Prescribing Continuous Kidney Replacement Therapy in the ICU]

By modality, CVVHDF represents the most widely utilized approach, as it integrates diffusion and convection mechanisms to enable concurrent clearance of small solutes and middle molecular weight substances. This positions it as particularly relevant in septic acute kidney injury and multi-organ failure, where renal dysfunction is often accompanied by systemic inflammation and hemodynamic instability.[NCBI Bookshelf — Hemodialysis | NIH/PMC — Prescribing Continuous Kidney Replacement Therapy in the ICU]

Continuous veno-venous hemofiltration (CVVH) remains a key modality in cases requiring convective clearance, particularly when clinical priorities include controlled fluid removal and enhanced middle-molecule clearance. It is typically employed in hemodynamically unstable patients where gradual solute and volume management is preferred over intermittent dialysis.

CVVHD is important in diffusion-led metabolic correction, especially when urea, creatinine, and electrolyte control are the main clinical priorities. Quanta’s expanded FDA clearance for CVVHD and SCUF supports this modality in compact acute-care settings, showing that vendors are positioning CVVHD as part of flexible ICU renal support rather than only conventional dialysis infrastructure.[NCBI Bookshelf — Hemodialysis | FDA — K222067 SC+ Hemodialysis Device 510(k) Premarket Notification]

 

Application Analysis

Acute kidney injury represents the primary clinical indication for continuous renal replacement therapy. AKI occurs in approximately 50–60% of critically ill ICU patients in certain cohorts, with an estimated 5–15% requiring kidney replacement therapy, directly supporting demand for CRRT systems, filters, blood circuits, dialysates, and replacement fluids in high-acuity intensive care settings.[NIH/PMC — Association of Hospital-Level Continuous Kidney Replacement Therapy Utilization and Patient Outcomes]

Sepsis-associated acute kidney injury represents the highest-acuity application segment. Sepsis contributes to approximately 45–70% of AKI cases, with reported SA-AKI incidence ranging from 14–87% depending on patient population and diagnostic criteria. This is commercially significant, as septic AKI patients frequently require vasopressor support, mechanical ventilation, and multi-organ management, resulting in prolonged CRRT utilization and higher consumable consumption.[NIH/PMC — Biomarkers of Sepsis-Induced Acute Kidney Injury | NIH/PMC — Epidemiology of Sepsis-Associated Acute Kidney Injury in Critically Ill Patients | NIH/PMC — Sepsis-Associated Acute Kidney Injury]

Pediatric and neonatal acute kidney injury represents a smaller patient volume but carries high clinical significance. The AWARE study reported that approximately one in four children admitted to 32 pediatric intensive care units developed AKI, with 12.6% progressing to severe AKI. These outcomes support the use of dedicated pediatric CRRT systems such as CARPEDIEM, where reduced circuit volume and precise ultrafiltration control are critical to safety.[NIH/PMC — Epidemiology of Acute Kidney Injury in Critically Ill Children and Young Adults | FDA — DEN180055 CARPEDIEM System De Novo Classification | NIH/PMC — Cefepime Dosing in a Critically Ill Neonate Receiving Continuous Renal Replacement Therapy]

Fluid overload is a key trigger for initiating pediatric and neonatal CRRT. Clinical evidence indicates that critically ill children with higher degrees of fluid overload prior to CRRT initiation experience increased mortality compared with those treated earlier, reinforcing the clinical importance of timing and fluid management and supporting demand for specialized pediatric CRRT systems and consumables.[NIH/PMC — Fluid Overload in Critically Ill Children | PubMed — Fluid Overload and Mortality in Children Receiving Continuous Renal Replacement Therapy]

Cardiac surgery-associated acute kidney injury represents an important clinical application area for continuous renal replacement therapy. Reported incidence of acute kidney injury following congenital cardiac surgery ranges between 20% and 60%, while pediatric extracorporeal membrane oxygenation data indicate an incidence of 81.4% in cardiac surgery sub-populations and a requirement for continuous renal replacement therapy in 52.2% of post-cardiac surgery patients compared with 30.2% in other cohorts. These findings support the role of CRRT in cardiac intensive care units and pediatric cardiac surgical programs.[NIH/PMC — Acute Kidney Injury Predictors and Outcomes After Cardiac Surgery in Children With Congenital Heart Disease | NIH/PMC — Acute Kidney Injury Post-Cardiac Surgery in Infants and Children | NIH/PMC — Acute Kidney Injury in Pediatric Patients on Extracorporeal Membrane Oxygenation]

 

What Is Moving CRRT Adoption

The primary adoption driver is the increasing clinical complexity of acute kidney injury management in intensive care units. Demand for continuous renal replacement therapy rises in settings involving septic shock, severe acute kidney injury, cardiac surgery–related complications, trauma, and multi-organ dysfunction. These patients often require continuous modalities due to the risk of hemodynamic instability associated with intermittent dialysis, reinforcing CRRT’s role in tertiary hospitals, academic medical centers, and critical care networks.[NCBI Bookshelf — Continuous Renal Replacement Therapy | NIH/PMC — Prescribing Continuous Kidney Replacement Therapy in the ICU]

Market expansion is also supported by a well-established installed base of FDA-cleared systems. PrisMax enables multiple CRRT modalities and is indicated for patients weighing 20 kg or more with acute renal failure and/or fluid overload. CARPEDIEM addresses neonatal and pediatric applications, while Quanta provides a compact platform cleared for CVVHD and SCUF. Collectively, these systems reflect a diversified technology landscape spanning full-scale ICU platforms, pediatric-specific systems, and compact multi-therapy devices.

Another key growth factor is high consumable utilization. As a continuous therapy, CRRT requires prolonged use of filters, circuits, fluids, and disposables, resulting in significantly higher procedural consumption compared with intermittent modalities. Consequently, hospital procurement decisions are increasingly influenced by circuit performance, filter lifespan, set compatibility, fluid management efficiency, alarm burden, and clinical training support, favoring integrated ecosystem-based offerings over standalone devices.

Workflow constraints within intensive care units further contribute to adoption. CRRT is resource-intensive and highly dependent on nursing staff availability, with ongoing workforce shortages increasing demand for systems that minimize interruptions, simplify setup, enhance alarm management, and improve prescription adherence. Features such as intelligent alarm systems, predefined therapy profiles, automated effluent handling, and fluid removal compensation are therefore becoming commercially relevant as they directly address ICU operational efficiency.

 

North America Continuous Renal Replacement Therapy Market

North America represents the leading regional market for continuous renal replacement therapy, driven primarily by the United States, which combines advanced intensive care unit infrastructure, a broad base of FDA-cleared devices, established critical care nephrology practice, pediatric specialty ICUs, and high-acuity hospital networks. Demand is reinforced by a high incidence of severe acute kidney injury in ICU settings, including cases associated with sepsis, trauma, cardiac surgery, and post-operative complications, where continuous renal support is often preferred over intermittent dialysis.

The U.S. market is supported by a diversified portfolio of approved and cleared CRRT systems. PrisMax is FDA-cleared for continuous renal replacement therapy in patients weighing 20 kg and above with acute renal failure and/or fluid overload and supports SCUF, CVVH, CVVHD, and CVVHDF modalities. CARPEDIEM provides pediatric ICUs with a regulated CRRT platform for patients weighing 2.5–10 kg. The 2023 FDA 510(k) clearance for Quanta expanded its compact system to include CVVHD and SCUF, alongside intermittent hemodialysis and sustained low-efficiency dialysis capabilities. These approvals are clinically significant as they enable adult ICU care, pediatric applications, and space-constrained critical care settings within a unified treatment framework.[FDA — K193482 PrisMax Control Unit 510(k) Summary | FDA — DEN180055 CARPEDIEM System De Novo Classification | FDA — K222067 SC+ Hemodialysis Device 510(k) Premarket Notification | NIH/PMC — Cefepime Dosing in a Critically Ill Neonate Receiving Continuous Renal Replacement Therapy]

North America also maintains a strong recurring consumables base, with CRRT programs in intensive care units dependent on continuous supply of hemofilters, blood tubing sets, pre-connected circuits, dialysates, and replacement fluids. Baxter’s ST Set clearance reinforced this ecosystem by introducing a single-use extracorporeal circuit compatible with PrisMax and Prismaflex systems. This structure enhances the attractiveness of the U.S. market for integrated suppliers capable of delivering hardware, consumables, fluids, training, and service support within bundled hospital procurement frameworks.

Recent innovation activity is likewise concentrated in the United States. Talphera’s NEPHRO CRRT study is evaluating Niyad, a nafamostat-based anticoagulant, for use in extracorporeal circuits among CRRT patients who are unable to tolerate heparin or present with elevated bleeding risk. The study is designed as a prospective, double-blind trial across up to 14 U.S. intensive care units and includes approximately 70 adult patients, with a primary endpoint assessing post-filter activated clotting time within the first 24 hours. This development represents a meaningful pipeline signal, as circuit clotting remains a key operational limitation in continuous renal replacement therapy delivery.[ClinicalTrials.gov — Nafamostat Efficacy in Phase 3 Registrational CRRT Study (NEPHRO) | SEC EDGAR — Talphera NEPHRO CRRT Study Disclosure]

The U.S. market growth is not driven by the emergence of CRRT, but by the increasing standardization of ICU acute kidney injury management, greater consumable utilization, and growing reliance on integrated device ecosystems that reduce clinical workload while preserving treatment precision. North America’s strength lies in the convergence of FDA-cleared platforms, advanced tertiary ICU infrastructure, pediatric critical care capability, and continued advancements in anticoagulation strategies and workflow optimization.

 

Recent Developmental Direction in the CRRT Market

The most significant recent shift in the CRRT market is the transition from hardware availability toward therapy efficiency. While the clinical role of CRRT is well established in hospital settings, current competition is increasingly defined by circuit lifespan, setup time, alarm frequency, fluid balance accuracy, consumable utilization cost, and integration within ICU workflows.

Baxter/Vantive’s PrisMax ecosystem reflects this evolution through multi-modality functionality, compatible CRRT solutions and filter sets, digital support tools, advanced alarm systems, predefined therapy profiles, automated effluent management, and improved fluid removal accuracy. These enhancements are clinically relevant in high-acuity ICU environments where CRRT is delivered continuously, and even incremental reductions in interruptions or setup complexity can translate into meaningful gains in operational efficiency.

Pediatric CRRT is increasingly transitioning from improvised clinical management toward the use of dedicated, purpose-built devices. The FDA classification of CARPEDIEM for 2.5–10 kg patients establishes a more clearly defined regulatory pathway for neonatal and low-weight pediatric renal support. This distinction is clinically relevant, as pediatric CRRT requires lower circuit volumes, greater flow precision, and tighter ultrafiltration control compared with adult therapies.

Compact acute-care systems are also gaining clinical relevance as ICU requirements evolve. Quanta’s expanded clearance for CVVHD and SCUF reflects broader industry efforts to reduce device footprint and enhance deployment flexibility within critical care settings. Its bagless CRRT design and on-demand dialysate generation model address operational constraints related to space utilization, nursing workload, and consumable management in hospital environments.

Anticoagulation represents one of the most active pipeline areas in the CRRT market. The Niyad CRRT trial does not introduce a new renal replacement platform but instead addresses a central operational limitation of the category, namely circuit clotting. Improvements in anticoagulation strategies that extend filter lifespan without increasing bleeding risk could enhance treatment continuity, reduce circuit exchanges, and lower overall clinical workload. As a result, innovation in anticoagulation remains commercially significant even within a relatively mature device segment.[ClinicalTrials.gov — Nafamostat Efficacy in Phase 3 Registrational CRRT Study (NEPHRO) | SEC EDGAR — Talphera NEPHRO CRRT Study Disclosure]

 

Evolving Market Landscape

The CRRT market is progressing into a more operationally mature phase. Its initial commercial positioning was defined by ICU-based availability of renal replacement platforms, while its current evolution is characterized by multi-modality systems, pediatric-specific CRRT solutions, compact acute-care devices, improved fluid management, optimized disposable circuits, and anticoagulation strategies aimed at extending circuit longevity.

CRRT systems continue to represent the primary capital equipment layer; however, consumables and associated fluids are increasingly central to long-term revenue generation. As CRRT is delivered as an ongoing therapy rather than a one-time purchase, hospitals continuously rely on filters, circuits, fluids, anticoagulation components, training, and service support. Accordingly, control over the broader clinical and operational ecosystem has become more important than standalone device placement.

CVVHDF is expected to remain the most strategically important modality, as it addresses the combined diffusive and convective clearance requirements of complex ICU-associated acute kidney injury. SCUF and CVVHD are anticipated to gain incremental relevance in specific clinical scenarios, particularly fluid overload management and compact system deployment. Pediatric CRRT is likely to remain lower in overall volume but high in clinical significance, as FDA-cleared systems such as CARPEDIEM enable precision renal support for patient populations that cannot be safely managed using standard adult platforms.

Overall, the Continuous Renal Replacement Therapy market should be characterized as a mature but high-value segment of critical care nephrology. Its growth will be driven by the rising burden of severe AKI, sepsis-associated renal failure, cardiac surgery–related complications, and fluid overload, alongside broader adoption of FDA-cleared CRRT systems, improvements in circuit design and anticoagulation strategies, and increasing demand for integrated platforms that enhance safety and operational manageability in ICU renal support.

 

Continuous Renal Replacement Therapy Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 1.62 Billion
Revenue Forecast in 2032	USD 2.85 Billion
Overall Growth Rate	CAGR of 7.3% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Product Type, By Modality, By End User, By Geography
By Product Type	CRRT Systems, CRRT Consumables, Dialysates & Replacement Fluids
By Modality	CVVH, CVVHDF, CVVHD, SCUF
By Application	Acute Kidney Injury, Sepsis-Associated Acute Kidney Injury, Fluid Overload, Pediatric & Neonatal Acute Kidney Injury, Cardiac Surgery-Associated Acute Kidney Injury
By End User	Hospitals, ASCs, Dialysis Clinics, Others
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country Scope	U.S., UK, Germany, China, India, Japan, Brazil, UAE
Market Drivers	Rise in AKI cases, ICU infrastructure expansion, AI-driven CRRT automation
Customization Option	Available upon request